EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cannara Biotech's Enterprise Value is $131.98 Mil.
Cannara Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was $11.59 Mil. Therefore, Cannara Biotech's EV-to-FCF for today is 11.39.
The historical rank and industry rank for Cannara Biotech's EV-to-FCF or its related term are showing as below:
LOVFF'
s EV-to-FCF Range Over the Past 10 Years
Min: -61.23 Med: -3.51 Max: 183.08
Current: 11.39
During the past 8 years, the highest EV-to-FCF of Cannara Biotech was 183.08. The lowest was -61.23. And the median was -3.51.
LOVFF's EV-to-FCF is ranked better than 73.88% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs LOVFF: 11.39
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cannara Biotech's PE Ratio (TTM) for today is calculated as:
Cannara Biotech's share price for today is $1.2135.
Cannara Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.073.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cannara Biotech EV-to-FCF Related Terms
Cannara Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's EV-to-FCF falls into.
Cannara Biotech's current Enterprise Value is $131.98 Mil.
Cannara Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a EV-to-FCF of 11.39 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #146 out of 559 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Cannara Biotech's EV-to-FCF too high?
Cannara Biotech's current EV-to-FCF is 11.39. The Drug Manufacturers industry median EV-to-FCF is 20.02. Cannara Biotech's value of 11.39 is 43.1% below this industry median. Based on the distribution chart, Cannara Biotech ranks #146 out of 559 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #146 out of 559 companies for EV-to-FCF. This puts Cannara Biotech in the upper half of its industry. The industry median EV-to-FCF is 20.02. Cannara Biotech's value of 11.39 is 43.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current EV-to-FCF of 11.39 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current EV-to-FCF is 11.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current EV-to-FCF is 11.39 and 43.1% below the Drug Manufacturers industry median of 20.02. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current EV-to-FCF is 11.39 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
EV-to-FCF: 11.39
GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
Industry Position: 43.1% below the Drug Manufacturers median (#146 of 559)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
